ixmyelocel-T
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ischemic Dilated Cardiomyopathy (IDCM)
Conditions
Ischemic Dilated Cardiomyopathy (IDCM)
Trial Timeline
Feb 20, 2013 → Mar 7, 2018
NCT ID
NCT01670981About ixmyelocel-T
ixmyelocel-T is a phase 2 stage product being developed by Vericel for Ischemic Dilated Cardiomyopathy (IDCM). The current trial status is completed. This product is registered under clinical trial identifier NCT01670981. Target conditions include Ischemic Dilated Cardiomyopathy (IDCM).
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01670981 | Phase 2 | Completed |
| NCT01483898 | Phase 3 | Completed |
| NCT01020968 | Phase 2 | Completed |
| NCT00765518 | Phase 2 | Completed |
| NCT00505219 | Phase 3 | Completed |
Competing Products
20 competing products in Ischemic Dilated Cardiomyopathy (IDCM)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aspirin, Clopidogrel | Yuhan | Pre-clinical | 23 |
| DS-1040b + Placebo | Daiichi Sankyo | Phase 1/2 | 41 |
| DS-1040b + Aspirin | Daiichi Sankyo | Phase 1 | 33 |
| DS1040b + Placebo | Daiichi Sankyo | Pre-clinical | 23 |
| Pharmacological intensification based on olmesartan | Daiichi Sankyo | Phase 2 | 52 |
| Regadenoson | Astellas Pharma | Phase 1 | 33 |
| YM872 (zonampanel), t-PA (alteplase) | Astellas Pharma | Phase 2 | 52 |
| Regadenoson | Astellas Pharma | Approved | 85 |
| ASP2246 | Astellas Pharma | Phase 1/2 | 41 |
| Gadolinium + Adenosine | Astellas Pharma | Phase 2/3 | 65 |
| XY03-EA + XY03-EA Placebo | Sun Pharmaceutical | Phase 2 | 52 |
| Redasemtide + Placebo | Shionogi | Phase 2 | 52 |
| Statin | Shionogi | Approved | 85 |
| fospropofol + propofol | Eisai | Phase 2 | 52 |
| PDE5 Inhibitors | Eli Lilly | Pre-clinical | 23 |
| SB623 Implant (2.5M) + SB623 Implant (5.0M) | Sumitomo Pharma | Phase 2 | 52 |
| Mesenchymal stem cell + Placebo | Rohto Pharmaceutical | Phase 2 | 52 |
| Elezanumab + Placebo | AbbVie | Phase 2 | 52 |
| Balovaptan + Placebo | Roche | Phase 2 | 52 |
| Repatha | Amgen | Approved | 84 |